In obese and type 2 diabetic mouse models, decreased plasma adiponectin levels lead to insulin resistance and dyslipidemia, but appropriate administration of adiponectin improved these pathological conditions [35]. Here, ADIPOQ is linked to type 2 diabetes mellitus.